Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
CAPR · Why this verdict
Why Capricor Therapeutics (CAPR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The entire pipeline is concentrated in a single program with a sole-source supply chain dependent on donor hearts — any adverse regulatory outcome or supply constraint forecloses the entire investment thesis in a single event. Bear case | Over 12 months, binary risk will remain unresolved and the stock will trade with volatility characteristic of a pre-approval catalyst, with the range of outcomes spanning near-zero to a large positive return. | →Stable |
| CounterConcentration cuts both ways: if Deramiocel receives a positive regulatory determination, the entire value of the pipeline crystallizes at once and there is no offsetting drag from underperforming assets. | ||
Short interest stands at 21% of the float, the put/call ratio is at an extreme 8.13, and implied volatility is 165% — the options and short markets are pricing in a high probability of a negative outcome. Risk breakdown | Over 12 months, if the bearish positioning is correct, the stock will decline toward or below the $24.85 stop reference as negative developments unfold; if it is wrong, a forced short-covering event could produce an outsized move in the opposite direction. | →Stable |
| CounterExtreme put/call ratios and short interest can become their own catalyst: if a positive regulatory signal emerges, the magnitude of forced covering could drive a short squeeze that temporarily overshoots fair value. | ||
Free cash flow is negative, the Piotroski F-Score is 2 out of 9, and three of the last four quarterly results missed consensus estimates with an average shortfall of roughly 24.6% — the company is burning cash faster than its own guidance implies. Earnings | Over 12 months, if this trajectory continues, quarterly cash burn will persist at or above recent levels and earnings will continue to miss consensus, further pressuring the equity. | →Stable |
| CounterPre-revenue pipeline companies typically show deteriorating near-term financials as they approach a regulatory inflection; the miss streak may reflect accelerating investment spend rather than fundamental operational failure, and a single approval event would immediately render trailing cash burn irrelevant. | ||
The quality score of 1.2 sits far below the minimum threshold of 4.0, with no competitive moat, negative free cash flow, and a Piotroski F-Score of 2 out of 9 — the business does not yet meet the baseline conditions required for a conventional investment. Quality breakdown | Over 12 months, quality metrics will remain below the minimum floor until the pipeline generates revenue, and the stock will carry a structural discount for the absence of financial durability. | →Stable |
| CounterQuality metrics are fundamentally backward-looking for pre-approval biotechs; the market correctly prices the forward probability of regulatory success rather than trailing cash flows, so the quality floor failure describes the current state but does not determine the outcome. | ||
The entire pipeline is concentrated in a single program with a sole-source supply chain dependent on donor hearts — any adverse regulatory outcome or supply constraint forecloses the entire investment thesis in a single event.
→StableBear case
- Expectation
- Over 12 months, binary risk will remain unresolved and the stock will trade with volatility characteristic of a pre-approval catalyst, with the range of outcomes spanning near-zero to a large positive return.
CounterConcentration cuts both ways: if Deramiocel receives a positive regulatory determination, the entire value of the pipeline crystallizes at once and there is no offsetting drag from underperforming assets.
Short interest stands at 21% of the float, the put/call ratio is at an extreme 8.13, and implied volatility is 165% — the options and short markets are pricing in a high probability of a negative outcome.
→StableRisk breakdown
- Expectation
- Over 12 months, if the bearish positioning is correct, the stock will decline toward or below the $24.85 stop reference as negative developments unfold; if it is wrong, a forced short-covering event could produce an outsized move in the opposite direction.
CounterExtreme put/call ratios and short interest can become their own catalyst: if a positive regulatory signal emerges, the magnitude of forced covering could drive a short squeeze that temporarily overshoots fair value.
Free cash flow is negative, the Piotroski F-Score is 2 out of 9, and three of the last four quarterly results missed consensus estimates with an average shortfall of roughly 24.6% — the company is burning cash faster than its own guidance implies.
→StableEarnings
- Expectation
- Over 12 months, if this trajectory continues, quarterly cash burn will persist at or above recent levels and earnings will continue to miss consensus, further pressuring the equity.
CounterPre-revenue pipeline companies typically show deteriorating near-term financials as they approach a regulatory inflection; the miss streak may reflect accelerating investment spend rather than fundamental operational failure, and a single approval event would immediately render trailing cash burn irrelevant.
The quality score of 1.2 sits far below the minimum threshold of 4.0, with no competitive moat, negative free cash flow, and a Piotroski F-Score of 2 out of 9 — the business does not yet meet the baseline conditions required for a conventional investment.
→StableQuality breakdown
- Expectation
- Over 12 months, quality metrics will remain below the minimum floor until the pipeline generates revenue, and the stock will carry a structural discount for the absence of financial durability.
CounterQuality metrics are fundamentally backward-looking for pre-approval biotechs; the market correctly prices the forward probability of regulatory success rather than trailing cash flows, so the quality floor failure describes the current state but does not determine the outcome.
TrendMatrix Research · core thesis
Engine thesis — one sentence
This is a pre-revenue, cash-burning single-asset pipeline company with three earnings misses in four quarters, a quality score far below the minimum acceptable floor, and extreme bearish positioning — the sizable analyst upside is entirely contingent on a single regulatory event for Deramiocel, making this a high-risk binary situation rather than a conventional investment.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.6 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 5.4 |
- ▸Uptrend pullback (RSI 39) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 139%
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.2 |
- ▸Notable insider selling — $1,639,088 (0.122% of mkt cap)
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.1 |
| growth rank | 5.0 |
Technical
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.1 |
| support resistance | 9.1 |
| 52w position | 1.1 |
| gap | 5.0 |
Risk (lower is worse)
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 22%
- ▸High IV: 117%
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- ASYMMETRY:7.2>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:37d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.6<4.5
Warning (0)
none
Reward-to-Risk
7.19
Upside
+107.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.3B) below institutional reach
SuitabilitySpeculative — Drawdown -44% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.6<4.5.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Technical at 6.1; the weakest are Quality at 1.2, Catalyst at 2.5, and Risk (lower is worse) at 3.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 7.19 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn With Worsening Misses
Trip ifEPS surprise turns positive (above 0%) for 2 consecutive quarters, indicating cash burn is stabilizing relative to expectations.
- P2Single Asset Pipeline Binary Risk
Trip ifDeramiocel receives an adverse FDA regulatory decision or a Complete Response Letter, sending the stock below $24.85.
- P3Extreme Bearish Market Positioning
Trip ifShort interest falls below 10% over 3 consecutive months, indicating the bearish positioning is unwinding.
- P4Quality Far Below Minimum Floor
Trip ifPiotroski F-Score rises above 5 for 2 consecutive quarters as the pipeline begins generating initial commercial revenue.